Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study.

about

Free fatty acid receptor 1 agonist, MR1704, lowers blood glucose levels in rats unresponsive to the sulfonylurea, glibenclamide.

P2860

Q47591876-A80358A8-6E6F-4338-B912-4F845C7DCC01

P2860

Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study.

Item

http://www.wikidata.org/entity/Q38792265

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Fasiglifam for glycaemic contr ...... III, placebo-controlled study.

@en

type

Item

label

Fasiglifam for glycaemic contr ...... III, placebo-controlled study.

@en

prefLabel

Fasiglifam for glycaemic contr ...... III, placebo-controlled study.

@en

P1476

Fasiglifam for glycaemic contr ...... III, placebo-controlled study.

@en

P2093

Charles Cao

http://www.w3.org/2001/XMLSchema#string

Douglas Lee

http://www.w3.org/2001/XMLSchema#string

John Marcinak

http://www.w3.org/2001/XMLSchema#string

Zhan Ye

http://www.w3.org/2001/XMLSchema#string

P2860

The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids.

Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40.

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.

Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes.

GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.

GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes.

Optimization of GPR40 Agonists for Type 2 Diabetes.

Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion.

P31

scholarly article

P356

10.1111/DOM.13004

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28493502

http://www.w3.org/2001/XMLSchema#string

P921

placebo

Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study.

about

P2860

P2860

Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P921